# Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

> **NCT00044759** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Hematologic Neoplasms

## Interventions

- **DRUG:** Piperacillin/Tazobactam (Tazocin)

## Key facts

- **NCT ID:** NCT00044759
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2003-01
- **Target enrollment:** — (—)
- **Last updated:** 2007-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044759, "Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00044759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*